Ovid Therapeutics Inc (NASDAQ: OVID) on Friday, soared 8.91% from the previous trading day, before settling in for the closing price of $0.57. Within the past 52 weeks, OVID’s price has moved between $0.56 and $3.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 344.59% over the past five years. The company achieved an average annual earnings per share of 37.16%. With a float of $56.87 million, this company’s outstanding shares have now reached $71.01 million.
Let’s look at the performance matrix of the company that is accounted for 40 employees. In terms of profitability, gross margin is -8.52%, operating margin of -10980.45%, and the pretax margin is -5146.14%.
Ovid Therapeutics Inc (OVID) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ovid Therapeutics Inc is 19.92%, while institutional ownership is 52.54%. The most recent insider transaction that took place on Jan 27 ’25, was worth 4,971. In this transaction President and COO of this company bought 6,810 shares at a rate of $0.73, taking the stock ownership to the 34,935 shares. Before that another transaction happened on Mar 18 ’24, when Company’s CEO bought 18,248 for $2.76, making the entire transaction worth $50,364. This insider now owns 3,616,715 shares in total.
Ovid Therapeutics Inc (OVID) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.77% during the next five years compared to 18.87% growth over the previous five years of trading.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Ovid Therapeutics Inc (OVID) is currently performing well based on its current performance indicators. A quick ratio of 5.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 69.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Ovid Therapeutics Inc (NASDAQ: OVID) saw its 5-day average volume 0.33 million, a negative change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 18.50%. Additionally, its Average True Range was 0.06.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 6.29%, which indicates a significant decrease from 35.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.49% in the past 14 days, which was higher than the 60.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8216, while its 200-day Moving Average is $1.2989. Nevertheless, the first resistance level for the watch stands at $0.6552 in the near term. At $0.6928, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.7369. If the price goes on to break the first support level at $0.5735, it is likely to go to the next support level at $0.5294. The third support level lies at $0.4918 if the price breaches the second support level.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
Market capitalization of the company is 43.85 million based on 71,010K outstanding shares. Right now, sales total 390 K and income totals -52,340 K. The company made 170 K in profit during its latest quarter, and -14,010 K in sales during its previous quarter.
